Solid Biosciences Positioned For Next-Gen Duchenne Muscular Dystrophy Treatment Success: Analyst
Solid Biosciences Positioned For Next-Gen Duchenne Muscular Dystrophy Treatment Success: Analyst
The therapy uses the AAV-SLB101 capsid and a specialized cargo (nNOS binding domain) to potentially boost dystrophin expression compared to earlier-generation treatments.Wedbush initiated coverage on Solid Biosciences, Inc. (NASDAQ:SLDB), a gene therapy company focused on treating Duchenne muscular dystrophy (DMD).
Wedbush開始報道Solid Biosciences, Inc.（納斯達克股票代碼：SLDB），這是一家專注於治療杜興氏肌肉萎縮症（DMD）的基因療法公司。
DMD is a genetic disease that causes progressive muscle weakness and wasting.
DMD 是一種遺傳性疾病，會導致漸進性肌肉無力和消瘦。
SGT-003 is the leading program in Solid Biosciences' pipeline, with plans to advance additional projects toward clinical trials in 2025.
SGT-003是Solid Biosciences正在研發的領先項目，計劃在2025年推進更多臨床試驗項目。
The therapy uses the AAV-SLB101 capsid and a specialized cargo (nNOS binding domain) to potentially boost dystrophin expression compared to earlier-generation treatments.
與前一代的治療相比，該療法使用 AAV-SLB101 衣殼和特殊載體（nnOS 結合域）有可能促進肌營養不良蛋白的表達。
While first-generation gene therapy for Duchenne muscular dystrophy (DMD) opens new treatment possibilities, there is still room for improvement. The analyst writes that Solid Biosciences' innovative approach and novel capsid technology could enhance microdystrophin delivery.
儘管杜興氏肌肉萎縮症（DMD）的第一代基因療法開闢了新的治療可能性，但仍有改進的餘地。這位分析師寫道，Solid Biosciences的創新方法和新的衣殼技術可以增強微肌營養素的輸送。
Although the company's pipeline offers multiple opportunities, current projections focus only on SGT-003 for DMD.
儘管該公司的產品線提供了多種機會，但目前的預測僅集中在DMD的SGT-003上。
The most significant near-term milestone for Solid Biosciences is the initial Phase 1/2 INSPIRE DUCHENNE trial results, expected in the first quarter of 2025.
Solid Biosciences最重要的短期里程碑是INSPIRE DUCHENNE的第1/2期初步試驗結果，預計將於2025年第一季度公佈。
Approving Sarepta Therapeutics Inc's (NASDAQ:SRPT) Elevidys was a key milestone in treating Duchenne muscular dystrophy (DMD), but it's only the beginning. Newer treatments with better and more reliable results are still needed.
批准Sarepta Therapeutics Inc（納斯達克股票代碼：SRPT）的Elevidys是治療杜興氏肌肉萎縮症（DMD）的關鍵里程碑，但這僅僅是個開始。仍然需要具有更好、更可靠結果的新療法。
Wedbush analyst writes, "We see Solid Biosciences in a "solid" position to deliver a next-gen therapeutic option."
Wedbush分析師寫道：「我們認爲Solid Biosciences在提供下一代治療選擇方面處於 「穩固」 的地位。」
Wedbush writes that Solid Biosciences' stock trade at around $5 each, with about $4 per share in cash providing some downside protection.
Wedbush寫道，Solid Biosciences的股票每股交易價格約爲5美元，每股約4美元的現金提供了一些下行保護。
Assuming Solid Biosciences' SGT-003 program follows a timeline similar to Sarepta's Elevidys, even a one-year delay would lower the price target to $11 per share (current price target of $16)—still above the current trading price.
假設Solid Biosciences的SGT-003計劃遵循的時間表與薩雷普塔的Elevidys類似，那麼即使延遲一年，也會將目標股價降至每股11美元（目前的目標股價爲16美元），仍高於當前的交易價格。
With other programs yet to be included in the valuation, the analyst sees strong potential and initiates with an Outperform rating.
由於其他項目尚未包括在估值中，分析師認爲潛力巨大，因此首先給出了跑贏大盤的評級。
Solid Biosciences ended the third quarter of 2024 with approximately $171.1 million in cash, cash equivalents, and available-for-sale securities, with an anticipated cash runway into 2026.
Solid Biosciences在2024年第三季度結束時擁有約1.711億美元的現金、現金等價物和可供出售證券，預計現金流將持續到2026年。
Price Action: SLDB stock is up 3.21% at $4.83 at the last check on Friday.
價格走勢：在週五的最後一次支票中，SLDB股價上漲3.21％，至4.83美元。
- Gilead Unveils New Yearly HIV Injection To Offer Hope for Less Frequent Preventive Dosing
- 吉利德推出新的年度HIV注射劑，爲減少預防性給藥頻率帶來希望